title: Effect of oxymetazoline nasal spray on intraocular pressure and retrobulbar hemodynamics.
abstract: OBJECTIVE
  To determine the effect of oxymetazoline nasal spray on intraocular pressure and retrobulbar hemodynamics in patients with open-angle glaucoma and to compare the results with those measured in healthy control participants.
  
  
  METHODS
  Controlled, prospective clinical trial.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  Thirty patients with open-angle glaucoma and 30 healthy volunteers as controls were topically self-administered oxymetazoline nasal spray three times a day (one spray in each nostril of 0.05% concentration) for 5 days continuously.
  
  
  METHODS
  Intraocular pressure and retrobulbar hemodynamics were measured in glaucomatous and normal eyes at baseline and at the end of oxymetazoline application .
  
  
  RESULTS
  Oxymetazoline nasal spray lowered intraocular pressure significantly in both the glaucoma group (p = .02) and the control group (p = .001) after 5 days of treatment. The systemic parameters in the glaucoma and control groups (systolic blood pressure, p = .14 and p = .17; diastolic blood pressure, p = .18 and p = .49; and pulse rate, p = .06 and p = .50, respectively) did not show statistically significant differences during the study period. Additionally, except with a significant decrease in the resistivity index of the central retinal artery in the glaucoma patients (p = .001), oxymetazoline nasal spray did not result in any significant changes in the retrobulbar hemodynamics in both the glaucoma and control groups.
  
  
  CONCLUSIONS
  This study showed that a 5-day treatment with oxymetazoline nasal spray reduced intraocular pressure in both healthy controls and patients with glaucoma under treatment. In addition, it had no significant adverse effects on the retrobulbar hemodynamics.
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kirikkale University, Kirikkale, Turkey. osman.arikan@gediknet.com
authors.forename: Osman Kursat
authors.initials: OK
authors.lastname: Arikan
authors.forename: Cengiz
authors.initials: C
authors.lastname: Akarsu
authors.forename: Birsen
authors.initials: B
authors.lastname: Unal
authors.forename: Ahmet
authors.initials: A
authors.lastname: Ergin
authors.forename: Can
authors.initials: C
authors.lastname: Koç
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D001299:Audiometry; D001783:Blood Flow Velocity / Q000187:drug effects; D005260:Female; D005902:Glaucoma, Open-Angle / Q000503:physiopathology*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D014663:Nasal Decongestants / Q000008:administration & dosage; D009880:Ophthalmic Artery / Q000503:physiopathology; D009915:Orbit / Q000098:blood supply; D010109:Oxymetazoline / Q000008:administration & dosage*; D012161:Retinal Artery / Q000503:physiopathology; D013566:Sympathomimetics / Q000008:administration & dosage*
chemical_list: D014663:Nasal Decongestants; D013566:Sympathomimetics; D010109:Oxymetazoline